Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Blood. 2020 Jul 2;136(1):137-139. doi: 10.1182/blood.2020006216.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Betacoronavirus / drug effects
  • COVID-19
  • Coronavirus Infections / etiology*
  • Cytokine Release Syndrome / complications*
  • Cytokine Release Syndrome / drug therapy*
  • Female
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / therapy
  • Humans
  • Immunotherapy, Adoptive / adverse effects*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / etiology*
  • Risk Factors
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab